Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 2Neuroendocrine Tumors 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 12pembrolizumab 7Carboplatin 7Cisplatin 6Docetaxel 5sargramostim 4Taxes 4Cyclophosphamide 4Amifostine 4Trastuzumab 3Polymerase Chain Reaction 3Nivolumab 3Irinotecan 3Gemcitabine 3Etoposide 3talazoparib 2aldesleukin 2Vorinostat 2Vinorelbine 2SS1(dsFv)PE38 2Pemetrexed 2Interleukin-12 Subunit p35 2Interleukin-12 2Immunoenzyme Techniques 2Gene Expression Profiling 2Flow Cytometry 2Filgrastim 2Erlotinib Hydrochloride 2tocilizumab 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × taxane × Thoracic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡